Lobular Carcinoma

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Also Known As:
Carcinoma, Lobular; Carcinomas, Lobular; Lobular Carcinomas
Networked: 630 relevant articles (9 outcomes, 56 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Breast Neoplasms (Breast Cancer)
2. Noninfiltrating Intraductal Carcinoma (DCIS)
3. Hyperplasia
4. Adenocarcinoma
5. Meningeal Carcinomatosis


1. Dabbs, David J: 9 articles (03/2014 - 01/2007)
2. Daling, Janet R: 8 articles (06/2014 - 08/2002)
3. Li, Christopher I: 7 articles (06/2014 - 10/2003)
4. Jonkers, Jos: 6 articles (04/2015 - 11/2006)
5. Lakhani, Sunil R: 6 articles (01/2015 - 01/2005)
6. Hunt, Kelly K: 6 articles (01/2014 - 11/2006)
7. Malone, Kathleen E: 5 articles (06/2014 - 12/2002)
8. Reis-Filho, Jorge S: 5 articles (07/2013 - 04/2002)
9. Simpson, Peter T: 4 articles (01/2015 - 01/2005)
10. Eusebi, Vincenzo: 4 articles (07/2013 - 11/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lobular Carcinoma:
1. Cadherins (E-Cadherin)IBA
2. TamoxifenFDA LinkGeneric
3. Estrogens (Estrogen)FDA Link
4. Progesterone Receptors (Progesterone Receptor)IBA
5. CateninsIBA
6. docetaxel (Taxotere)FDA Link
7. Cytarabine (Cytosar-U)FDA LinkGeneric
8. Proteins (Proteins, Gene)IBA
9. Keratins (Keratin)IBA
10. ParaffinIBA

Therapies and Procedures

1. Mastectomy (Mammectomy)
2. Drug Therapy (Chemotherapy)
3. Radiotherapy
4. Chemoprevention
12/01/2012 - "Women with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and severe ADH are at increased risk of breast cancer, but a systematic quantification of this risk and the efficacy of chemoprevention in the clinical setting is still lacking. "
02/01/2015 - "The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). "
01/01/2002 - "Chemoprevention with tamoxifen may be particularly beneficial to women with atypical hyperplasia, 5-year Gail model risk greater than 5%, lobular carcinoma-in-situ, or two or more first-degree relatives with breast cancer. "
12/01/2001 - "Younger women who do not have lobular carcinoma in situ or atypical ductal hyperplasia, or who may be at high risk of carrying a breast cancer predisposing gene, may be relatively resistant to tamoxifen chemoprevention. "
01/27/2009 - "Favourable results, that is cost saving or cost-effective, are found by both tamoxifen and raloxifene for the introduction of chemoprevention among extremely high-risk women such as having a history of atypical hyperplasia, a history of lobular carcinoma in situ or a 5-year predicted breast cancer risk of > or =5.01% starting at younger age, whereas unfavourable results, that is 'cost more and gain less' or cost-ineffective, are found for women with a 5-year predicted breast cancer risk of < or =5.00%. "
5. Segmental Mastectomy (Lumpectomy)